Moreover, this study indicates that the number of CD4+ and CD8+ TILs decreases with the development of new histological patterns, i.e., non-classic differentiations in more advanced tumors (pT3–pT4), which can be associated with lower tumor immunogenicity, resulting in stronger immune tolerance to cancer. This evidence concerns the gene CD4 and neoplasm.